Journal of Clinical Oncology
Articles in this Issue
Profiling treatment-associated evolutionary dynamics in advanced urothelial cancer via deep whole exome sequencing of cell-free DNA.
4572 Background: Monitoring treatment response and identifying resistance mechanisms remain critical challenges in managing advanced bladder cancer. We in...
TROP-2 expression in germ cell tumors (GCT).
5031 Background: Trophoblast cell surface antigen 2 (TROP-2) is a tumor associated antigen overexpressed in several malignancies including breast and urot...
Elevated risk of multiple primary malignancies in esophageal cancer survivors: Incidence, patterns, and risk factors.
e16008 Background: Advancements in diagnostics and improved survival rates have raised a growing concern about the occurrence of multiple primary malignan...
Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).
4176 Background: PDAC is associated with a paucity of immune effector cells, low antigenicity, and immunosuppressive factors in the tumor microenvironment...
Liquid biopsy at an NCI comprehensive cancer center: Patterns of utilization, performance, and outcomes.
e20696 Background: Next generation sequencing is a fundamental diagnostic tool in non-small cell lung cancer (NSCLC). In tandem with tissue genomic testin...
Surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma.
e16222 Background: Advanced metastatic ICC was characterized by poor survival and limited therapeutic options. Surufatinib, a selective tyrosine kinase in...
Understanding patient anxiety at pre- and post-consultation with gynecologic oncology.
e24069 Background: Anxiety is highly prevalent among patients presenting for new oncology consultation and is a phenomenon that is not well-described in t...
Medium dose of TPF chemotherapy with concurrent radiotherapy and immunotherapy for locally advanced esophageal squamous cell carcinoma.
e16123 Background: Concurrent chemoradiotherapy is the standard treatment for local advanced esophageal squamous cell carcinoma (ESCC), but the prognosis...
Stratification of vulvar squamous cell carcinoma (VSCC) by HPV and P53 status to guide excision: CCTG VU.2 STRIVE study (NCT06358469).
TPS5637 Background: Early VSCC is treated surgically. The optimal approach to margin re-excision may depend on molecular subtype. HPV associated (HPV-A) V...
Out-of-pocket cost modeling of EUROPA trial arms for adjuvant breast cancer therapy: Five days of radiation versus five years of antiestrogen therapy.
519 Background: Optimal adjuvant therapy following breast-conserving surgery in adults with low-risk, early-stage breast cancer remains uncertain. Cost an...
An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005).
e12620 Background: HER2-low expressing breast cancer represents a heterogenous subtype with limited targeted therapeutic options. Disitamab Vedotin, a nov...
Genomic characteristics and their clinical significance in a large cohort of biliary tract cancers with more than 4,000 patients.
e16285 Background: Biliary tract cancers (BTCs) are mainly divided into cholangiocarcinoma (CHOL) and gallbladder cancer (GBC). Genomic characteristics of...
Racial differences in prevalence of coronary artery calcification among patients undergoing lung cancer screening.
e23341 Background: Coronary artery calcification (CAC) is a known risk factor for coronary heart disease. Lung cancer screening (LCS) with low-dose comput...
Differential prognostic significance of distant and locoregional recurrence on survival in surgically resected non-small cell lung cancer post-chemotherapy: Multicenter dynamic prediction with landmark model.
8062 Background: Recurrence remains a significant challenge in patients with surgically resected non-small cell lung cancer (NSCLC) following adjuvant che...
Comparative outcomes of systemic therapy vs. locoregional therapies in hepatocellular carcinoma with portal vein thrombosis.
e16317 Background: Portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC) presents a significant challenge, with treatment options including locor...
A phase II, single-arm, open-label clinical trial to evaluate the combination of cadonilimab injection and gut microbiota modulation in the treatment of persistent, recurrent, or metastatic cervical cancer following second-line therapy.
TPS5622 Background: Current treatment options for cervical cancer include surgery, radiotherapy, and chemotherapy. For persistent, recurrent, or metastati...
The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine–tipiracil.
e15542 Background: Treatment for refractory metastatic colorectal cancer is still a challenge. In the previous studies, the overall survival would increas...
Extensive lymph node dissection and overall survival in colon cancer: A systematic review and meta-analysis.
e15662 Background: Colon cancer remains a leading cause of cancer-related mortality, with surgical resection and lymph node dissection (LND) being key to...
Pioneering cancer survivorship care in Latin America: Early results from the OC sobre VIVER program in Brazil.
1640 Background: Cancer survivorship poses a growing challenge, especially in low- and middle-income settings. The OC SobreVIVER program, launched in Octo...
Effect of hospital systems on surgical outcomes in cancer patients.
e16449 Background: Individual hospitals are rapidly consolidating into large healthcare systems. While evidence exists on volume-outcome relationships for...
Burden of cervical cancer in Uzbekistan: Trends in incidence and mortality.
e17517 Background: Cervical cancer is the third most frequent disease among women in the world, which accounts more than 9% of the total number of newly d...
Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
11558 Background: Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the col...
Efficacy and safety results of a multi-center phase I study of utidelone capsule, a novel oral microtubule inhibitor, in advanced solid tumor patients.
3030 Background: Utidelone is a novel microtubule inhibitor, whose injectable formulation (UTD1) has been approved for advanced breast cancer in China sin...
Real-world effectiveness of lurbinectedin in extensive stage small cell lung cancer (ES-SCLC).
e20133 Background: Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer that usually presents with disseminated disease and relapses with...
Trends and disparities in lung cancer mortality among older adults with chronic lower respiratory diseases: A nationwide analysis of US data from 1999 to 2020.
e22547 Background: Lung cancer is a leading cause of mortality among older adults with a history of chronic lower respiratory diseases (CLRD). Examining t...